RSS
Cosentyx
Novartis’ cosentyx to have blockbuster sales
The FDA’s recent approval of Novartis’ cosentyx for the treatment of adults with active ankylosing spondylitis (AS) and psoriatic arthritis (PsA), will propel the drug to blockbuster status, according to GlobalData analyst, Alexandra Annis Read more
Novartis’ Cosentyx gets FDA approval for arthritis treatment
The US Food and Drug Administration (FDA) has approved Novartis’ Cosentyx (secukinumab) for the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA) Read more
